A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

• Status: RECRUITING
• Trial end date: 2026-11-03

Summary

Primary Objective:

To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state

Secondary Objectives:

1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS.

2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS

3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS

• Phase: PHASE3

Details

• Lead Sponsor: Amgen